Evidence map›Paper›PMID 34257726›Full record

ArticleOncology letters2021

Diversity and shared T-cell receptor repertoire analysis in esophageal squamous cell carcinoma.

Tomoya Sudo, Akihiko Kawahara, Kazuo Ishi, Atsushi Mizoguchi, Sachiko Nagasu, Masashi Nakagawa, Masahiro Fujisaki, Haruhiro Hino, Kouhei Saisho, Hideaki Kaku and 5 more

Open access · diamondAbstract read
In one paragraph

Article in Oncology letters, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.2field-weighted citation impact, top 54% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 1 institution in 1 country.

Tomoya SudoDepartment of Surgery, Kurume University School of Medicine, Kurume, Fukuoka 830-0011, Japan.
Akihiko KawaharaDepartment of Hospital Diagnosis, Kurume University School of Medicine, Kurume, Fukuoka 830-0011, Japan.
Kazuo IshiBiostatistics Center, Kurume University School of Medicine, Kurume, Fukuoka 830-0011, Japan.
Atsushi MizoguchiDepartment of Immunology, Kurume University School of Medicine, Kurume, Fukuoka 830-0011, Japan.
Sachiko NagasuDepartment of Surgery, Kurume University School of Medicine, Kurume, Fukuoka 830-0011, Japan.
Masashi NakagawaDepartment of Surgery, Kurume University School of Medicine, Kurume, Fukuoka 830-0011, Japan.
Masahiro FujisakiDepartment of Surgery, Kurume University School of Medicine, Kurume, Fukuoka 830-0011, Japan.
Haruhiro HinoDepartment of Surgery, Kurume University School of Medicine, Kurume, Fukuoka 830-0011, Japan.
Kouhei SaishoDepartment of Surgery, Kurume University School of Medicine, Kurume, Fukuoka 830-0011, Japan.
Hideaki KakuDepartment of Surgery, Kurume University School of Medicine, Kurume, Fukuoka 830-0011, Japan.
Satoru MatonoDepartment of Surgery, Kurume University School of Medicine, Kurume, Fukuoka 830-0011, Japan.
Naoki MoriDepartment of Surgery, Kurume University School of Medicine, Kurume, Fukuoka 830-0011, Japan.
Jun AkibaDepartment of Hospital Diagnosis, Kurume University School of Medicine, Kurume, Fukuoka 830-0011, Japan.
Akira YamadaCancer Vaccine Development Division, Research for Innovative Cancer Therapy, Kurume University School of Medicine, Kurume, Fukuoka 830-0011, Japan.
Yoshito AkagiDepartment of Surgery, Kurume University School of Medicine, Kurume, Fukuoka 830-0011, Japan.
Kurume University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The tumor immune response is dependent on the interaction between tumor cells and the T-cell subset expressing the T-cell receptor (TCR) repertoire that infiltrates into the tumor microenvironment. The present study explored the diversity and shared TCR repertoires expressed on the surface of locoregional T cells and identified the T lymphocyte subsets infiltrating into esophageal squamous cell carcinoma (ESCC), in order to provide insight into the efficiency of immunotherapy and the development of a novel immune-oriented therapeutic strategy. A total of 53 patients with ESCC were enrolled in the present study, and immunohistochemical analysis of CD3, CD8, CD45RO, FOXP3, CD274, HLA class I and AE1/AE3 was performed. Digital pathological assessment was performed to evaluate the expression level of each marker. The clinicopathological significance of the immuno relation high (IR-Hi) group was assessed. Adaptor ligation PCR and next-generation sequencing were performed to explore the diversity of the TCR repertoire and to investigate the shared TCR repertoire in the IR-Hi group. Repertoire dissimilarity index (RDI) analysis was performed to assess the diversity of TCR, and the existence of shared TCRα and TCRβ was also investigated. Further stratification was performed according to the expression of markers of different T-cell subsets. Patients were stratified into IR-Hi and immuno relation low (IR-Lo) groups. Cancer-specific survival and recurrence-free survival rates were significantly improved in the IR-Hi group compared with in the IT-Lo group. The diversity of the TCR repertoire was significantly higher in the IR-Hi group. TCR repertoire analysis revealed 27 combinations of TCRα and 23 combinations of TCRβ VJ regions that were shared among the IR-Hi group. The IR-Hi group was divided into three clusters. Overall, the current findings revealed that the IR-Hi group maintained the diversity of TCR, and a portion of the IR-Hi cases held the T cells with shared TCR repertoires, implying recognition of shared antigens. The prognosis of patients with ESCC was affected by the existence of immune response cells and may possibly be stratified by the T-cell subsets.

Indexed as

comprehensive T-cell receptor repertoire analysisesophageal squamous cell carcinoma

Identifiers

PMID34257726
PMCPMC8243081
OpenAlexW3177283657

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.